rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2008-4-2-76-80rpcardio-1096Research ArticleCURRENT QUESTIONS OF CLINICAL PHARMACOLOGYАКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИFROM THE SHORT ACTING NIFEDIPINE TO AMLODIPINE AND FIXED COMBINATIONS. HIGHLIGHTS THE PROBLEM FROM THE CURRENT GUIDELINES POINT OF VIEWОТ КОРОТКОДЕЙСТВУЮЩЕГО НИФЕДИПИНА К АМЛО- ДИПИНУ И ФИКСИРОВАННЫМ КОМБИНАЦИЯМ. ПРО- БЛЕМА В СВЕТЕ СОВРЕМЕННЫХ РЕКОМЕНДАЦИЙ ПО ЛЕЧЕНИЮ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИКательницкаяЛ. И.KatelnitskayaL. I.ХаишеваЛ. А.HaishevaL. A.Ростовский государственный медицинский университетРоссияRostov State Medical UniversityRussian Federation200829012016427680Copyright © Katelnitskaya L.I., Haisheva L.A., 20162016Кательницкая Л.И., Хаишева Л.А.Katelnitskaya L.I., Haisheva L.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/1096

Calcium antagonists (CA) therapy of patients with arterial hypertension is focused on the base of current recommendations. Results of some large clinical trials confirm high antihypertensive efficacy of this therapeutic class. Special attention is devoted to implementation of fixed combinations on the basis of CA. Advantages of these combinations in hypertension therapy are discussed.

Статья посвящена применению антагонистов кальция (АК) при артериальной гипертонии (АГ) с позиций современных рекомендаций. Приведены данные крупных исследований, подтверждающих высокую антигипертензивную эффективность этого класса препаратов. Особое внимание уделяется применению при АГ фиксированных комбинаций с АК, обосновываются их преимущества по сравнению со стандартной терапией.

артериальная гипертонияантагонисты кальцияфиксированные комбинацииarterial hypertensioncalcium antagonistsReferencesНациональные рекомендации по профилактике, диагностике и лечению ар- териальной гипертонии (Второй пересмотр). Кардиоваскулярная терапия и профилактика 2004; 3(3):105–20.Национальные рекомендации по профилактике, диагностике и лечению ар- териальной гипертонии (Второй пересмотр). Кардиоваскулярная терапия и профилактика 2004; 3(3):105–20.National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care partial update. London: National Institute for Health and Clinical Excellence; 2006.National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care partial update. London: National Institute for Health and Clinical Excellence; 2006.The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiolody. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105– 87.The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiolody. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105– 87.MacMahon S, Chalmers J. Blood pressure lowering and ACE inhibition for the avoidance of cardiac and cerebral events. Eur Heart J 2003;24(5):391-3.MacMahon S, Chalmers J. Blood pressure lowering and ACE inhibition for the avoidance of cardiac and cerebral events. Eur Heart J 2003;24(5):391-3.Карпов Ю.А. Применение антагонистов кальция у больных артериальной ги- пертонией и ишемической болезнью сердца: современное состояние вопроса. Кардиология 2000;(10):52-5.Карпов Ю.А. Применение антагонистов кальция у больных артериальной ги- пертонией и ишемической болезнью сердца: современное состояние вопроса. Кардиология 2000;(10):52-5.Метелица В.И. Справочник по клинической фармакологии сердечно–сосу- дистых лекарственных средств. М.: Бином; 2002.Метелица В.И. Справочник по клинической фармакологии сердечно–сосу- дистых лекарственных средств. М.: Бином; 2002.Psaty B.M., Heckbert S.R., Koepsell T.D. et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-25.Psaty B.M., Heckbert S.R., Koepsell T.D. et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-25.Furberg C.D., Psaty B.M., Meyer J.V. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31.Furberg C.D., Psaty B.M., Meyer J.V. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31.Pahor M., Gurinik J.M., Corti M.C. et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995;43:1191-7.Pahor M., Gurinik J.M., Corti M.C. et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995;43:1191-7.Malacoff R.F., Lorell B.H., Mudge G.H. et al. Beneficial effects of nifedipine on regional myocardial blood flow in patients with coronary artery disease. Circulation 1982; 65 (1 Pt 2): I32-I37.Malacoff R.F., Lorell B.H., Mudge G.H. et al. Beneficial effects of nifedipine on regional myocardial blood flow in patients with coronary artery disease. Circulation 1982; 65 (1 Pt 2): I32-I37.Kugiyama K., Yasue H., Horio Y. et al. Effects of propranolol and nifedipine on exercise-induced attack in patients variant angina: assessment by exercise thallium- 201 myocardial scintigraphy with quantitative rotational tomography. Circulation 1986;74 (2):374-80.Kugiyama K., Yasue H., Horio Y. et al. Effects of propranolol and nifedipine on exercise-induced attack in patients variant angina: assessment by exercise thallium- 201 myocardial scintigraphy with quantitative rotational tomography. Circulation 1986;74 (2):374-80.Warwick D. FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards. JAMA 1996; 275:423-4.Warwick D. FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards. JAMA 1996; 275:423-4.Марцевич С.Ю. Нифедипин. Различные лекарственные формы в лечении сердечно-сосудистых заболеваний. Кардиология 1998;(11):66-74.Марцевич С.Ю. Нифедипин. Различные лекарственные формы в лечении сердечно-сосудистых заболеваний. Кардиология 1998;(11):66-74.Mason R.P., Walter M.F., Trumbore M.W. et al. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 1999;31:275-81Mason R.P., Walter M.F., Trumbore M.W. et al. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 1999;31:275-81Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000;102(13):1503-10.Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000;102(13):1503-10.Zanchetti A., Bond G., Hennig M. et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422–7Zanchetti A., Bond G., Hennig M. et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422–7Nissen S.E., Tuzcu E.M., Libby P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217– 26.Nissen S.E., Tuzcu E.M., Libby P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217– 26.Dahlöf B., Sever P.S., Poulter N.R. et al for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895- 906.Dahlöf B., Sever P.S., Poulter N.R. et al for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895- 906.ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–5.Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–5.Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.Бойцов С.А. Комбинированная терапия артериальной гипертензии с позиций профилактики сердечно-сосудистыx осложнений и патогенеза. Consilium Medicum 2004; 2(приложение):23-6.Бойцов С.А. Комбинированная терапия артериальной гипертензии с позиций профилактики сердечно-сосудистыx осложнений и патогенеза. Consilium Medicum 2004; 2(приложение):23-6.Farsang C. a HAMLET Vizsgalok neveben (2004) A lisinopril es az amlodipin kombinaciojanak elonyei az antihypertensiv terapiaban. A Hypertoniaban adott AMlodipin 5 mg es Lisinopril 10 mg tablettak hatekonysaganak es toleralhatosaganak osszehasonlito vizsgalata kulon es Egyutt alkalmazott Terapiakent (HAMLET). Multicentrikus vizsgalat eredmenyei. [Advantages of lisinopril amlodipin fix combination therapy in hypertension. A comparative study of the efficacy and tolerability of amlodipin 5 mg and lisinopril 10 mg administrated separately and in combination in hypertension] Hypertonia es nephrologia, 8(2):72–8.Farsang C. a HAMLET Vizsgalok neveben (2004) A lisinopril es az amlodipin kombinaciojanak elonyei az antihypertensiv terapiaban. A Hypertoniaban adott AMlodipin 5 mg es Lisinopril 10 mg tablettak hatekonysaganak es toleralhatosaganak osszehasonlito vizsgalata kulon es Egyutt alkalmazott Terapiakent (HAMLET). Multicentrikus vizsgalat eredmenyei. [Advantages of lisinopril amlodipin fix combination therapy in hypertension. A comparative study of the efficacy and tolerability of amlodipin 5 mg and lisinopril 10 mg administrated separately and in combination in hypertension] Hypertonia es nephrologia, 8(2):72–8.Архипов В.В. Сочетание антагонистов кальция и ингибиторов АПФ у больных артериальной гипертензией. Врач 2007;(8): 62-4.Архипов В.В. Сочетание антагонистов кальция и ингибиторов АПФ у больных артериальной гипертензией. Врач 2007;(8): 62-4.Маколкин В.И. Совершенствование комбинированной терапии – путь к улучшению результатов лечения артериальной гипертонии. РМЖ 2007; 15(16):1238–41.Маколкин В.И. Совершенствование комбинированной терапии – путь к улучшению результатов лечения артериальной гипертонии. РМЖ 2007; 15(16):1238–41.

The authors declare that there are no conflicts of interest present.